Mezzion Pharma Appoints Jefferson Gregory To Board Of Directors

Mezzion Pharma Appoints Jefferson Gregory To Board Of Directors

SEOUL, Korea, Oct. 9, 2014 /PRNewswire/ -- Mezzion Pharma Co. Ltd., announced the appointment of Jefferson Gregory, B.S. Pharm., J.D., HD to the Company's Board of Directors. Mr. Gregory was the co-founder of King Pharmaceutical, Inc. and served as its Chairman and Chief Executive Officer.  During his tenure as Chairman and CEO, King Pharmaceuticals' net revenue rose from approximately $870.0 Million to over $1.5 Billion when it was acquired by Pfizer in 2010.  He is currently the Chairman and CEO of Rockward Pharmaceuticals and Rockward Pharmaceutical Consultants, LLC.  Mr. Gregory graduated from the University of Maryland in 1979 with a BS degree in Pharmacy and from the University of Maryland in 1985 with a Juris Doctorate Degree. He also holds an honorary Doctor of Laws degree conferred upon him by King College

Mr. Dean Park, Chairman, Mezzion Pharma, commented that "We are extremely pleased to have Mr. Gregory join our Board.  He brings considerable depth of knowledge and experience in the pharmaceutical industry from finance and acquisition to operations.  We look forward to his guidance as Mezzion Pharma moves to file its first New Drug Application (NDA) for its lead compound, udenafil, a new phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction."

Mezzion Pharma has recently filed an Investigational New Drug Application (IND) with the FDA for the study of udenafil to treat adolescents who have undergone the Fontan surgical palliation for single ventricle heart defects and has initiated the first clinical trial for this indication. There are approximately 19,000 Fontan patients in the US and the company expects that the use of udenafil in such patients will be eligible for orphan-drug designation.

Mezzion Pharma Co. Ltd.

Mezzion Pharma is a publicly-listed biotech company in Korea focusing on the development of new drugs.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to FDA review and approval, product development and acceptance, manufacturing, competition, and/or other factors, which are outside the control of the Company.

Mr. Won Geun KIM
General Manager
Tel: +82 2 560 8008
Fax: + 82 2 563 6517
Email: [email protected]

SOURCE Mezzion Pharma Co. Ltd.